EGFR and lung adenocarcinoma: In the 34 patients with stage IV lung adenocarcinoma treated with a first-line EGFR TKI (Table A3), those with concordant EGFR mutation test results in liquid/tissue biopsy had significantly poorer PFS than those with discordant results (p = 0.0032) (Figure A1a).